BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol 2020;73:1548-56. [PMID: 32777323 DOI: 10.1016/j.jhep.2020.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression. Cells 2021;10:2759. [PMID: 34685739 DOI: 10.3390/cells10102759] [Reference Citation Analysis]
2 Peiffer KH, Zeuzem S. [Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2022. [PMID: 35006288 DOI: 10.1007/s00103-021-03481-z] [Reference Citation Analysis]
3 Calvaruso V, Craxì A. Reply to: "Hepatic benefits of HCV cure: Don't forget coagulation!". J Hepatol 2021;74:969. [PMID: 33345830 DOI: 10.1016/j.jhep.2020.12.015] [Reference Citation Analysis]
4 Compagnoni S, Bruno EM, Madonia G, Cannizzaro M, Madonia S. Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched. World J Gastroenterol 2021; 27(21): 2771-2783 [PMID: 34135553 DOI: 10.3748/wjg.v27.i21.2771] [Reference Citation Analysis]
5 Bauer D, Kozbial K, Schwabl P, Chromy D, Simbrunner B, Stättermayer AF, Pinter M, Steindl-munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.02.013] [Reference Citation Analysis]
6 Crespo J, Díaz-González Á, Iruzubieta P, Llerena S, Cabezas J. SARS-CoV-2 massive testing: A window of opportunity to catch up with HCV elimination. J Hepatol 2021;74:966-7. [PMID: 33039405 DOI: 10.1016/j.jhep.2020.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
7 Tacke F, Klinker H, Boeker KHW, Merle U, Link R, Buggisch P, Hüppe D, Cornberg M, Sarrazin C, Wedemeyer H, Berg T, Mauss S; DHC-R. Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry. Hepatol Commun 2022. [PMID: 35666055 DOI: 10.1002/hep4.2015] [Reference Citation Analysis]
8 Doica IP, Florescu DN, Oancea CN, Turcu-Stiolica A, Subtirelu MS, Dumitra G, Rogoveanu I, Gheonea DI, Ungureanu BS. Telemedicine Chronic Viral Hepatitis C Treatment during the Lockdown Period in Romania: A Pilot Study. Int J Environ Res Public Health 2021;18:3694. [PMID: 33916226 DOI: 10.3390/ijerph18073694] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Tosetti G, Degasperi E, Farina E, D'Ambrosio R, Soffredini R, Borghi M, La Mura V, Primignani M, Lampertico P. Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy. Am J Gastroenterol 2021;116:1342-4. [PMID: 33606382 DOI: 10.14309/ajg.0000000000001158] [Reference Citation Analysis]
10 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
11 Mandorfer M, Turon F, Lens S, Baiges A, García-Criado Á, Darnell A, Belmonte E, Ferrusquía-Acosta J, Magaz M, Perez-Campuzano V, Olivas P, Bauer D, Casanovas G, Torres F, Mariño Z, Forns X, Hernández-Gea V, García-Pagán JC. Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. Liver Int 2021. [PMID: 34242479 DOI: 10.1111/liv.15009] [Reference Citation Analysis]
12 Semmler G, Mandorfer M. Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.031] [Reference Citation Analysis]
13 Zanetto A, Simioni P, Russo FP. Hepatic benefits of HCV cure: Don't forget coagulation! J Hepatol 2021;74:967-8. [PMID: 33340585 DOI: 10.1016/j.jhep.2020.10.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
15 Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00155-7. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Reference Citation Analysis]
16 Nagao Y, Tsuji M. Effects of Hepatitis C Virus Elimination by Direct-Acting Antiviral Agents on the Occurrence of Oral Lichen Planus and Periodontal Pathogen Load: A Preliminary Report. Int J Dent 2021;2021:8925879. [PMID: 34804168 DOI: 10.1155/2021/8925879] [Reference Citation Analysis]
17 Quaranta MG, Ferrigno L, Tata X, D'Angelo F, Coppola C, Ciancio A, Bruno SR, Loi M, Giorgini A, Margotti M, Cossiga V, Brancaccio G, Dallio M, De Siena M, Cannizzaro M, Cavalletto L, Massari M, Mazzitelli M, De Leo P, Laccabue D, Baiocchi L, Kondili LA. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort. BMC Infect Dis 2021;21:413. [PMID: 33947337 DOI: 10.1186/s12879-021-06053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yoo HW, Park JY, Kim SG, Jung YK, Lee SH, Kim MY, Jun DW, Jang JY, Lee JW, Kwon OS. Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents. Sci Rep 2022;12:193. [PMID: 34996920 DOI: 10.1038/s41598-021-03272-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers 2022;14:828. [DOI: 10.3390/cancers14030828] [Reference Citation Analysis]
20 Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, Yu ML, Peng CY. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). J Gastroenterol Hepatol 2021. [PMID: 33963615 DOI: 10.1111/jgh.15538] [Reference Citation Analysis]
21 Kouroumalis E, Voumvouraki A. Hepatitis C virus: A critical approach to who really needs treatment. World J Hepatol 2022; 14(1): 1-44 [DOI: 10.4254/wjh.v14.i1.1] [Reference Citation Analysis]
22 Montaldo C, Terri M, Riccioni V, Battistelli C, Bordoni V, D'Offizi G, Prado MG, Trionfetti F, Vescovo T, Tartaglia E, Strippoli R, Agrati C, Tripodi M. Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response. J Hepatol 2021:S0168-8278(21)01901-2. [PMID: 34271004 DOI: 10.1016/j.jhep.2021.07.003] [Reference Citation Analysis]
23 Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Chen Y, Chang T, Chen C, Cheng P, Lo C, Mo L, Chen C, Huang C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Huang J, Yang C, Hu J, Lin C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Dai C, Kao J, Chuang W, Lin H, Chen C, Tseng K, Yu M; on behalf of TACR investigators. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. Viruses 2022;14:333. [DOI: 10.3390/v14020333] [Reference Citation Analysis]